Industries > Pharma > Global Next-Generation Antibody Therapies Market Forecast 2017-2027

Global Next-Generation Antibody Therapies Market Forecast 2017-2027

Antibody-Drug Conjugates (ADC), Biosimilar Antibodies, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments and Antibody-Like Proteins (ALPs)

PUBLISHED: 25 May 2017
PAGES: 249
PRODUCT CODE: PHA0195

Clear
WOOCS 2.2.1

The global next-generation antibody therapies market is expected to grow at a CAGR of 35.9% in the first half of the forecast period. The market is expected to grow at a CAGR of 22.4% from 2016-2027. The market is estimated at $3.1bn in 2016 and $14.1bn in 2021.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 249-page report you will receive 133 charts – all unavailable elsewhere.

The 249-page report provides clear detailed insight into the global next-generation antibody therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Next-Generation Antibody Therapies Market forecasts from 2017-2027

• Along with revenue prediction for the overall world market for next-generation antibody therapies, our investigation shows forecasts to 2027 for the following five submarkets:
– Antibody-drug conjugates (ADCs)
– Engineered antibodies
– Bispecific antibodies
– Antibody fragments and antibody-like proteins (ALPs)
– Biosimilar antibody therapies

• How will leading next-generation antibody therapies perform to 2027 at world level? Our study forecasts individual revenues of seven products:
– Adcetris
– Kadcyla
– Gazyva/Gazyvaro
– Poteligeo
– Removab
– Blincyto
– Kalbitor

• Our analyses show individual revenue forecasts to 2027 for these regional markets:
– US
– EU5 group
– Asia-Pacific region
– Latin America
– Rest of the World

Global Next-Generation Antibody Therapies Market Forecast 2017-2027

• This report discusses issues affecting the next-generation antibody therapies market:
– R&D for next generation antibodies – explore technologies and potentials
– Challenges with current monoclonal antibody (mAb) therapies
– Big pharma companies investing in next-generation antibody research and development
– Biosimilars and their effects on the next-generation antibody therapies market

• Our study discusses strengths, weaknesses, opportunities and threats as well as social, technological, economic and political factors that affect the next-generation antibody therapies market

Visiongain’s study is intended for anyone requiring commercial analyses for the next-generation antibody therapies market. You find data, trends and predictions.

Buy our report today Global Next-Generation Antibody Therapies Market Forecast 2017-2027: Antibody-Drug Conjugates (ADC), Biosimilar Antibodies, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments and Antibody-Like Proteins (ALPs).

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Next-Generation Antibody Therapies Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Next-Generation Antibody Therapies Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories